한국어
Quantus

IVIM Technology

A460470 · KOSDAQ
₩2,955+2.96%
2026-08-26 close

IVIM Technology — what's the grade? And what signals are flashing today?

The grade and valuation bands are below — free to read.

Loading chart…
Close
AI Insight

Why these signals fired — only backtest-proven edge, told honestly

Why this signalSignal guide

Moving-average alignment
No

No active signal.

New high + volume — the real recordrecord · not a prediction

Not this one stock, but every new-high-plus-volume pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-26)

Last 30 sessions
383 picks
Next-day win rate
51.1%
Avg next-day
-0.06%
vs market
-0.08%p

Beat the market on 47.8% of picks (each pick vs its own day’s market average).

Recent publish days (next-day win rate)
08-25 60%08-23 60%08-21 36.4%08-20 44.4%08-19 0%08-18 27.3%08-14 23.1%08-13 41.7%08-12 70%08-11 77.8%08-10 22.2%08-07 61.5%
This stock flashed this signal 1 time over the last ~2 years (see the signal history below for each date).

Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.

Trade plan

Decide the exit before you enter. Set what you are willing to lose first, and the share count follows — so you know the worst case before you buy.

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

This is a calculator, not advice, and it does not promise any outcome. You choose the stop and target — the button values (ATR, recent low/high) are observations from past prices. Actual fills depend on the order book and liquidity.

Valuation Grades

Relative to 291 건강관리 peers · not investment advice

C+
Overall: 건강관리 182/291 · top 62%
Factor composite · relative position in sector

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 10.41
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
10.41
Beneish M-Score

Statistical flag unavailable

Sloan accrual
8.39%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

0/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score0/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Not passed

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -194%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-08-26

건강관리

This stock is in 건강관리: revenue rank 266 of 287, share 0%.

266 / 2870%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6아이빔테크놀로지0%

Concentration

DistributedCR3 16.6%
HHI 201287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
14
Median P/B
1.47
Level
넓음
n
263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-120.7%
Interest coverage
-23.3x
Return on equity (ROE)
-12.8%

Operating margin −5pp

Operating loss
Interest coverageBase -23.3x adverse case -24.3x
Return on equity (ROE)Base -12.8% adverse case -14.9%

Revenue −15%

Interest coverage risk
Interest coverageBase -23.3x adverse case -19.8x
Return on equity (ROE)Base -12.8% adverse case -12.3%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -23.3x adverse case -16.8x
Return on equity (ROE)Base -12.8% adverse case -14.6%

Interest coverage limit

Already below the limit by 125.9pp

Interest coverage limit at an operating margin of 5.2%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-04-03

Suppliers disclosed by the company in its 2026-04-03 annual report.

Suppliers without disclosed amount

AxonLaserALCORIChromePMTPolygonCFIAPOFrameUSD

Financials at a glance

IVIM Technology's latest results and balance sheet. The bars track the last three periods.

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 김필한25.53%2026-01-02 · 증감 -0.20%p
  • 에이티넘인베스트12.61%2024-08-12 · 증감 +12.61%p
  • LB인베스트먼트5.24%2025-04-25 · 증감 -2.32%p

Recent filings

IVIM Technology's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

Signal history (last ~2 years)

Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.

New high + volume×1
26-05-08-27.7%
New MA alignment×4
26-06-17-30.1%26-05-21-9.2%26-05-18-2.4%26-04-30-3.6%

“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.

Like these rules? Run them automatically.

Quantus turns rules like these into backtests and automated trading — same team, free to start.

Quantus Signal · live data · not investment advice · Privacy Policy